Search Results - Lutz Jermutus

Refine Results
  1. 1
    Tailoring<i>in vitro</i>evolution for protein affinity or stability

    Tailoring<i>in vitro</i>evolution for protein affinity or stability by Lutz Jermutus, Annemarie Honegger, Falk Schwesinger, Jozef Hanes, Andreas Plückthun

    Published 2000
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Identification of cyclic peptides able to mimic the functional epitope of IgG1‐Fc for human FcyRI

    Identification of cyclic peptides able to mimic the functional epitope of IgG1‐Fc for human FcyRI by Stéphane Bonetto, Loredana Spadola, Andrew Buchanan, Lutz Jermutus, John Lund

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Exploiting protease activation for therapy

    Exploiting protease activation for therapy by Chloe Bleuez, Wolfgang F. Koch, Carole Urbach, Florian Hollfelder, Lutz Jermutus

    Published 2022
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Ribosome display efficiently selects and evolves high-affinity antibodies<i>in vitro</i>from immune libraries

    Ribosome display efficiently selects and evolves high-affinity antibodies<i>in vitro</i>from immune libraries by Jozef Hanes, Lutz Jermutus, Susanne Weber-Bornhauser, Hans Rudolf Bosshard, Andreas Plückthun

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Challenges and opportunities for non-antibody scaffold drugs

    Challenges and opportunities for non-antibody scaffold drugs by Rodrigo Vazquez-Lombardi, Tri Giang Phan, Carsten Zimmermann, David C. Lowe, Lutz Jermutus, Daniel Christ

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

    A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency by Matthieu Chodorge, Sara Züger, Christian U. Stirnimann, Christophe Briand, Lutz Jermutus, Markus G. Grütter, Ralph Minter

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study

    Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study by Rajaa Nahra, Tao Wang, Kishore M. Gadde, Jan Oscarsson, Michael Stümvoll, Lutz Jermutus, Boaz Hirshberg, Philip Ambery

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study

    MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study by Philip Ambery, Sebastian Klammt, Maximillian G. Posch, Marcella Petrone, Wenji Pu, Cristina M. Rondinone, Lutz Jermutus, Boaz Hirshberg

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates

    Unbinding forces of single antibody-antigen complexes correlate with their thermal dissociation rates by Falk Schwesinger, Robert Ros, Torsten Strunz, Dario Anselmetti, H.-J. Güntherodt, Annemarie Honegger, Lutz Jermutus, Louis Tiefenauer, Andreas Plückthun

    Published 2000
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis

    Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis by Sudha S. Shankar, Samuel J. Daniels, Darren Robertson, Janeli Sarv, José Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun J. Sanyal

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Probing a protein–protein interaction by <i>in vitro</i> evolution

    Probing a protein–protein interaction by <i>in vitro</i> evolution by George Thom, Alexis C. Cockroft, Andrew Buchanan, Cathy Joberty Candotti, E. Suzanne Cohen, David Lowne, Phill Monk, Celia P. Shorrock-Hart, Lutz Jermutus, Ralph Minter

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression

    Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression by Andrew Buchanan, Veronica Clementel, Rob Woods, Nicholas Harn, Michael A. Bowen, Wenjun Mo, Bojana Popovic, Steven M. Bishop, William F. Dall’Acqua, Ralph Minter, Lutz Jermutus, Vahe Bedian

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor

    Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor by Peter Ravn, Chaithanya Madhurantakam, Susan Kunze, Evelyn Matthews, Claire Priest, Siobhan O’Brien, Andie Collinson, Monika Papworth, Maria Fritsch-Fredin, Lutz Jermutus, Lambertus Benthem, M.G. Gruetter, Ronald H. Jackson

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type

    Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type by Steven Rust, Sandrine Guillard, Kris F. Sachsenmeier, Carl Hay, Max Davidson, Anders Karlsson, Roger Karlsson, Erin Brand, David Lowne, John Elvin, Matt Flynn, Gene Kurosawa, Robert E. Hollingsworth, Lutz Jermutus, Ralph Minter

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Dual <scp>glucagon‐like peptide</scp>‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity

    Dual <scp>glucagon‐like peptide</scp>‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity by Rajna Golubić, Jane Kennet, Victoria Parker, Darren Robertson, Dan Luo, Lars Hansen, Lutz Jermutus, Philip Ambery, Maria Ryaboshapkina, Manasa Surakala, Rhianna C. Laker, Michelle Venables, Albert Koulman, Adrian Park, Mark L. Evans

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

    Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling by Alan M. Sandercock, Steven Rust, Sandrine Guillard, Kris F. Sachsenmeier, Nick Holoweckyj, Carl Hay, Matt Flynn, Qihui Huang, Kuan Yan, Bram Herpers, Leo Price, Jo Soden, Jim Freeth, Lutz Jermutus, Robert E. Hollingsworth, Ralph Minter

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease

    Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney... by Victoria Parker, Thuong Hoang, Heike Schlichthaar, Fraser W. Gibb, Barbara Wenzel, Maximillian G. Posch, Ludger Rose, Yi‐Ting Chang, Marcella Petrone, Lars Hansen, Philip Ambery, Lutz Jermutus, Hiddo J.L. Heerspink, Rory J. McCrimmon

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β

    Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β by Simon J. Henderson, Christin Andersson, Rajesh Narwal, Juliette Janson, Tom J. Goldschmidt, Paulina Appelkvist, Anna Bogstedt, Ann-Charlott Steffen, Ulrich Haupts, Jan Tebbe, Per Ola Freskgård, Lutz Jermutus, Matthew Burrell, Susan B. Fowler, Carl I. Webster

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor

    LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor by Xuecai Ge, Hong Yang, Maria A. Bednarek, Hadas Galon-Tilleman, Peirong Chen, Michael Chen, Joshua S. Lichtman, Yan Wang, Olivier Dalmas, Yiyuan Yin, Hui Tian, Lutz Jermutus, Joseph Grimsby, Cristina M. Rondinone, Anish Konkar, Daniel D. Kaplan

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics

    The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics by Siva Charan Devanaboyina, Sandra Lynch, Raimund J. Ober, Sripad Ram, Dong Young Kim, Alberto Puig-Canto, Shannon Breen, Srinath Kasturirangan, Susan B. Fowler, Li Peng, Haihong Zhong, Lutz Jermutus, Herren Wu, Carl I. Webster, E. Sally Ward, Changshou Gao

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: